NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.